5WK0 Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Aligos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.73 |
| 52 Week High | US$25.50 |
| 52 Week Low | US$7.15 |
| Beta | 2.12 |
| 11 Month Change | 0% |
| 3 Month Change | -2.39% |
| 1 Year Change | -19.81% |
| 33 Year Change | -97.00% |
| 5 Year Change | n/a |
| Change since IPO | -97.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5WK0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -0.4% |
| 1Y | -19.8% | -16.7% | 7.1% |
Return vs Industry: 5WK0 underperformed the German Biotechs industry which returned -17.6% over the past year.
Return vs Market: 5WK0 underperformed the German Market which returned 9% over the past year.
Price Volatility
| 5WK0 volatility | |
|---|---|
| 5WK0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5WK0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 5WK0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 68 | Larry Blatt | www.aligos.com |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
Aligos Therapeutics, Inc. Fundamentals Summary
| 5WK0 fundamental statistics | |
|---|---|
| Market cap | €62.42m |
| Earnings (TTM) | -€72.50m |
| Revenue (TTM) | €5.65m |
11.0x
P/S Ratio-0.9x
P/E RatioIs 5WK0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5WK0 income statement (TTM) | |
|---|---|
| Revenue | US$6.00m |
| Cost of Revenue | US$73.04m |
| Gross Profit | -US$67.04m |
| Other Expenses | US$9.91m |
| Earnings | -US$76.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -20.73 |
| Gross Margin | -1,117.94% |
| Net Profit Margin | -1,283.19% |
| Debt/Equity Ratio | 0% |
How did 5WK0 perform over the long term?
See historical performance and comparison